Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Anders Bjartell

Showing results (1-10 of 325) with videos related to

Pageof 33
Sort By:
European Urology|March 12, 2015
Re: activity and safety of ODM-201 in patients with progressive metastatic castration-resistant prostate cancer (ARADES): an open-label phase 1 dose-escalation and randomised phase 2 dose expansion trialAnders Bjartell
European Urology|August 28, 2007
PSA and prostate cancer screening: the challenge of the new millenniumAnders Bjartell
European Urology|July 3, 2007
Words of wisdom. The 2005 International Society of Urological Pathology (ISUP) Consensus Conference on Gleason Grading of Prostatic CarcinomaAnders Bjartell
European Urology|August 30, 2011
Circulating tumour cells as surrogate biomarkers in castration-resistant prostate cancer trialsAnders Bjartell
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|February 28, 2019
New Hope in Prostate Cancer Precision Medicine? miRNA Replacement and EpigeneticsAnders Bjartell
European Urology|March 23, 2011
Genetic markers and the risk of developing prostate cancerAnders Bjartell
European Urology|April 2, 2022
Re: Performance of a Prostate-specific Membrane Antigen Positron Emission Tomography/Computed Tomography-derived Risk-stratification Tool for High-risk and Very High-risk Prostate CancerAnders Bjartell
European Urology|July 14, 2012
"A robot saved my life": is it a myth?Anders Bjartell
European Urology|May 13, 2023
Re: Niraparib and Abiraterone Acetate for Metastatic Castration-resistant Prostate CancerMartin Sjöström, Anders Bjartell
European Urology|March 12, 2015
Re: AR-V7 and resistance to enzalutamide and abiraterone in prostate cancerAseem Undvall Anand, Anders Bjartell
Pageof 33

Showing results (1-10 of 325) with videos related to

Sort By:
Pageof 33
European Urology|March 12, 2015
Re: activity and safety of ODM-201 in patients with progressive metastatic castration-resistant prostate cancer (ARADES): an open-label phase 1 dose-escalation and randomised phase 2 dose expansion trialAnders Bjartell
European Urology|August 28, 2007
PSA and prostate cancer screening: the challenge of the new millenniumAnders Bjartell
European Urology|July 3, 2007
Words of wisdom. The 2005 International Society of Urological Pathology (ISUP) Consensus Conference on Gleason Grading of Prostatic CarcinomaAnders Bjartell
European Urology|August 30, 2011
Circulating tumour cells as surrogate biomarkers in castration-resistant prostate cancer trialsAnders Bjartell
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|February 28, 2019
New Hope in Prostate Cancer Precision Medicine? miRNA Replacement and EpigeneticsAnders Bjartell
European Urology|March 23, 2011
Genetic markers and the risk of developing prostate cancerAnders Bjartell
European Urology|April 2, 2022
Re: Performance of a Prostate-specific Membrane Antigen Positron Emission Tomography/Computed Tomography-derived Risk-stratification Tool for High-risk and Very High-risk Prostate CancerAnders Bjartell
European Urology|July 14, 2012
"A robot saved my life": is it a myth?Anders Bjartell
European Urology|May 13, 2023
Re: Niraparib and Abiraterone Acetate for Metastatic Castration-resistant Prostate CancerMartin Sjöström, Anders Bjartell
European Urology|March 12, 2015
Re: AR-V7 and resistance to enzalutamide and abiraterone in prostate cancerAseem Undvall Anand, Anders Bjartell
Pageof 33